PMID- 23610530
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130424
LR  - 20211021
IS  - 1179-1373 (Print)
IS  - 1179-1373 (Electronic)
IS  - 1179-1373 (Linking)
VI  - 5
DP  - 2013
TI  - Greater ethnic diversity correlates with lower HIV prevalence in Africa: 
      justification for an alloimmunity vaccine.
PG  - 75-80
LID - 10.2147/HIV.S38922 [doi]
AB  - PURPOSE: After decades of research, AIDS continues to be a major pandemic and to 
      date, adaptive immunity vaccine designs have had little to no success. Data 
      indicate the alloimmune response is a potent mitigator of human immunodeficiency 
      virus (HIV) infection, for which experiments of nature should be demonstrable to 
      justify pursuit of an alloimmune vaccine strategy. We sought to determine if 
      large-scale alloimmune diversity correlates with lower HIV infection rates. 
      METHODS: Using published data of African linguistic groups to determine 
      sub-Saharan country ethnicity profiles as a proxy for human leukocyte antigen 
      (HLA) diversity, a correlation analysis was performed against respective 
      sub-Saharan country HIV infection rates. Ethnicity data from 37 sub-Saharan 
      nations in 2003 and from 38 nations in 2005 were used to calculate the 
      Meyers-Macintosh ethnic diversity score for each nation as the independent 
      variable. World Health Organization data on HIV infection rates for the same 
      countries were used as the dependent variable. The main outcome measure was the 
      correlation coefficient of ethnic diversity versus HIV infection rate. RESULTS: A 
      SIGNIFICANT NEGATIVE CORRELATION WAS SHOWN BETWEEN ETHNIC DIVERSITY AND HIV 
      INFECTION: for 2003 data, -0.4586 (two-tailed P-value of 0.0043); and, for 2005 
      data, -0.3866 (two-tailed P-value of 0.0165). CONCLUSION: In conjunction with 
      substantial evidence that alloimmunity confers protection against HIV 
      transmission and recent work identifying specific anti-HIV mechanisms, this 
      analysis strongly justifies an HLA-based alloimmune vaccine strategy against HIV.
FAU - Zamani, Christopher
AU  - Zamani C
AD  - Center for AIDS Health Disparities Research at Meharry Medical College, 
      Nashville, Tennessee, USA.
FAU - Elzey, Jared D
AU  - Elzey JD
FAU - Hildreth, James Ek
AU  - Hildreth JE
LA  - eng
GR  - U54 RR019192/RR/NCRR NIH HHS/United States
GR  - U54 RR026140/RR/NCRR NIH HHS/United States
PT  - Journal Article
DEP - 20130412
PL  - New Zealand
TA  - HIV AIDS (Auckl)
JT  - HIV/AIDS (Auckland, N.Z.)
JID - 101515943
PMC - PMC3628525
OTO - NOTNLM
OT  - AIDS
OT  - adaptive immunity
OT  - human leukocyte antigen (HLA)
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:01
PMCR- 2013/04/12
CRDT- 2013/04/24 06:00
PHST- 2013/04/24 06:00 [entrez]
PHST- 2013/04/24 06:00 [pubmed]
PHST- 2013/04/24 06:01 [medline]
PHST- 2013/04/12 00:00 [pmc-release]
AID - hiv-5-075 [pii]
AID - 10.2147/HIV.S38922 [doi]
PST - epublish
SO  - HIV AIDS (Auckl). 2013 Apr 12;5:75-80. doi: 10.2147/HIV.S38922. Print 2013.